Publish in this journal
Journal Information
Vol. 72. Issue 9.
Pages 781-783 (September 2019)
Download PDF
More article options
Vol. 72. Issue 9.
Pages 781-783 (September 2019)
Scientific letter
DOI: 10.1016/j.rec.2018.10.007
Full text access
The Multivalvular Score for Predicting the Outcome of Mitral Regurgitation in Aortic Stenosis Patients Treated With TAVI: Prospective Validation
El Multivalvular Score para predecir la evolución de la insuficiencia mitral en pacientes con estenosis aórtica tratados con TAVI: validación prospectiva
Pablo Cataláa, Ignacio J. Amat-Santosa,b,
Corresponding author

Corresponding author:
, Manuel Carrasco-Moralejab, Álvaro Aparisia, Carlos Cortésa, José A. San Romána,b
a Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario de Valladolid, Valladolid, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Article information
Full Text
Download PDF
Figures (1)
Tables (1)
Table 1. Comparison of the Main Clinical and Echocardiographic Characteristics of the Initial and the Validation Samples
Full Text
To the Editor,

Up to 45% of patients with severe aortic stenosis (AS) have concomitant moderate or severe mitral regurgitation (MR).1 The high rate of multivalvular disease is due to the elevated filling pressures of the left ventricle resulting from the increased afterload due to severe AS and the parallel deterioration of both valves due to the aging process. Clinical practice guidelines recommend surgical repair or replacement of both valves in this scenario, although this recommendation remains controversial due to the limited evidence and the higher mortality associated with this strategy.2 Indeed, many patients undergo single surgical or percutaneous aortic valve replacement. The growing use of transcatheter aortic valve implantation (TAVI) in these patients suggests an improvement in the degree of MR in more than 50% of cases, with a parallel decrease in the cardiac mortality rate during follow-up.3 Therefore, it is crucial to identify patients who could potentially improve in the concomitant degree of MR following TAVI. Previous studies have identified some predictors of MR persistence in this scenario, including calcification of the mitral apparatus, organic valvular disease, mitral annular dilatation, atrial fibrillation, left bundle branch block, and pulmonary hypertension.2 Recently Cortés et al. have determined the impact of these and other factors in 177 patients with moderate or severe MR who underwent TAVI and whose echocardiographic and computed tomography images were centrally analyzed.3 Following characterization of the main predictors of MR persistence, software named the Multivalvular Score was developed. This software is easy to use and helpful to the Heart Team when making clinical decisions about candidates for valve interventions (Figure 1A). This tool is available as open-access software for computers through a link,4 as a free app for smartphones, or as an analog numeric scale, as shown in Figure 1C. The calibration value was 3.960 (P=.776) and discrimination was 0.781 (95%CI, 0.671-0.892).

Figure 1.

A: interface of the “Multivalvular Score”. B: ROC curves showing sensitivity and specificity for the initial sample4 and for the validation sample. C: score assigned to each variable and range of scores associated with different likelihoods of mitral regurgitation persistence; the ROC curves below demonstrate an exceptional correlation of the logistic regression and the score system. 95%CI, 95% confidence interval; AUC, area under curve; LBBB, left bundle branch block; MR, mitral regurgitation; ROC, receiver operating characteristic; SE, standard error; SPPA, systolic pressure of pulmonary artery; TAVI, transcatheter aortic valve implantation.


By using this software, we aimed to perform a prospective validation of the score. A total of 144 patients with moderate or severe MR from 4 institutions who underwent TAVI between April, 2009 and June, 2016 were evaluated with the Multivalvular Score and clinical results 1 year after the procedure were compared with the predicted outcomes. The main clinical and imaging characteristics were similar to those of the original study3 and are summarized in Table 1.

Table 1.

Comparison of the Main Clinical and Echocardiographic Characteristics of the Initial and the Validation Samples

Characteristics  MR ≥ 3Initial sample4N=177  MR ≥ 3Validation sampleN=144  P 
Clinical characteristics
Age, y  81.3±6.3  80.9±5.2  .713 
Male  102 (57.6)  96 (66.7)  .098 
STS Score, %  5.1 [3.9-7.8]  4.7 [3.3-7.1]  .342 
Logistic EuroSCORE, %  12 [9-18]  11.2 [6.9-16.9]  .441 
Hypertension  129 (73.3)  101 (70.1)  .588 
Diabetes mellitus  61 (34.7)  52 (36.1)  .758 
Chronic kidney disease  44 (25)  35 (24.3)  .910 
Prior heart surgery  23 (13.1)  17 (11.8)  .748 
Prior atrial fibrillation  58 (33.1)  41 (28.1)  .407 
NYHA class III-IV  77 (44)  58 (40.3)  .110 
Echocardiographic characteristics
Aortic valve area, mm2  0.63 [0.5-0.78]  0.7 [0.4-0.7]  .899 
Peak gradient, mmHg  80.9±23.1  83.2±21.3  .789 
Mean gradient, mmHg  51.4±15.6  52.4±12.3  .882 
Left ventricular ejection fraction, %  60 [49.5-66]  62 [48-68]  .210 
SPPA, mmHg  50 [35-60]  47 [33-56]  .103 

Values are expressed as No. (%), mean±standard deviation, or median [25th-75th interquartile range], depending on variable distribution.

MR, mitral regurgitation; NS, nonsignificant; NYHA, New York Heart Association; SPPA, systolic pressure of pulmonary artery; STS, Society of Thoracic Surgeons.

MR improved by at least 1 degree according to European guidelines at the 6-month follow-up in 73 patients (50.7%) and the improvement persisted in 69 (47.9%) at 1 year. The sensitivity and specificity of the Multivalvular Score in this population were 0.821 and 0.652, respectively, as shown in Figure 1B (area under the curve=0.772 [95%CI, 0.663-0.881], P <.001). The 6-month mortality rate in these patients was 31.9% compared with 35% in the initial sample (P=NS).

The Multivalvular Score is the first tool fully available for clinical use that has demonstrated a certain capacity to predict the outcome of moderate or severe MR following TAVI. This scenario is often faced by the Heart Team and, until now, only surgical scores have been available. These scores can be used to determine the risk of dual valve replacement but are not useful to select which patients might benefit from more conservative approaches with single aortic valve replacement. Although there are certain limitations regarding the accuracy of the Multivalvular Score, its prospective validation opens a gate to more extensive use that will help to improve the accuracy of this tool, as well as to extend its applicability to alternative scenarios where more than 1 valve is severely affected.5,6

In conclusion, this research adds evidence confirming the constant improvement of MR following TAVI in half of the patients and validates the Multivalvular Score as a simple tool that helps to predict which patients with concomitant AS and moderate or severe MR will improve after isolated TAVI. Conversely, it is also crucial to identify those patients who will require a surgical, percutaneous, or hybrid strategy to repair both valves.


The project was funded by a grant from the Instituto de Salud Carlos III (PI14/00022) and by the Coronary and Structural Course (CSC).


We thank all the institutions that participated in the development of the Multivalvular Score: Hospital Clínico Universitario San Carlos, Madrid, Spain; Hospital Clínico Virgen de la Victoria, Málaga, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Hospital Universitario Marqués de Valdecilla, Santander, Spain; Hospital General Universitario de Albacete, Albacete, Spain; and the Quebec Heart and Lung Institute, Quebec, Canada.

L. Nombela-Franco, H.B. Ribeiro, M. Urena, et al.
Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequententity in the transcatheter aortic valve replacement era.
J Am Coll Cardiol, 63 (2014), pp. 2643-2658
B. Iung, G. Baron, E.G. Butchart, et al.
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on valvular heart disease.
Eur Heart J, 24 (2003), pp. 1231-1243
C. Cortés, I.J. Amat-Santos, L. Nombela-Franco, et al.
Mitral regurgitation after transcatheter aortic valve replacement: prognosis, imaging predictors, and potential management.
JACC Cardiovasc Interv., 9 (2016 Aug 8), pp. 1603-1614
Instituto de Ciencias del corazón (ICICOR). Multivalvular Score available at: Accessed 20 Sep 2018.
Amat-Santos IJ, J. Castrodeza, L. Nombela-Franco, et al.
Tricuspid but not Mitral Regurgitation Determines Mortality After TAVI in Patients With Nonsevere Mitral Regurgitation.
Rev Esp Cardiol., 71 (2018), pp. 357-364
F. Carrasco-Chinchilla, R. Estévez-Loureiro, L. Andraka, D. Arzamendi, X. Freixa, J. Suárez de Lezo.
Percutaneous Mitral Repair With MitraClip in Patients Treated With Transcatheter Aortic Valve Implantation.
Rev Esp Cardiol., 70 (2017), pp. 1144-1145
Copyright © 2019. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?